Avadel Pharmaceuticals Plc ADR (AVDL) Stock Price, Quote & News

Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 a...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 353 1 901 5201

Website: www.avadel.com

Address:

10 Earlsfort Terrace, Dublin, Ireland

tagebha Sep. 9 at 4:59 PM

$AVDL Here is a link to patents XWPharma has. https://patents.justia.com/assignee/xwpharma-ltd

0 · Reply

G101SPM Sep. 9 at 2:57 PM

G101SPM 8/7/2025, 7:33:09 AM $AVDL $11.64 bid. DAC (dollar average cost includes 6-transactions with partial SELLS at a profit to reduce cost to $8.98. EXIT $35.00 - LH.

0 · Reply

Its_Only_Money_369 Sep. 5 at 11:23 PM

$AVDL Just listened to fireside chat. Key take aways. Confirmation of many assumptions ive made over the last two days. Fact: XWpharma has been radio silent for nearly four years. Chat confirms Avadel approached XW roughly four and a half years ago. Assumptio: XW is developing designer drugs. Chat confirmed XW starts with the original compound and alters it during the manufacturing process. This creates a new molecule/drug. Chat confirmed they are confident FDA will a a modified molecule after successful studies based on president. XW targets FDA approved drugs with large addressable markets. Jazz pipeline today J&J tomorrow. It’s almost as if I was in charge of the teleprompter. This will be a money machine. Couldn’t be happier at the momeby.

1 · Reply

Its_Only_Money_369 Sep. 5 at 10:48 PM

$AVDL Posted on YMB $14.69 says AVDL is in has negotiated an agreement to buy WX pipeline or partner with them for development of designer drugs compounded with time release technology to skirt ODE and dominate the market in every way possible. Rearranging a single atom changes the molecule and creates a new drug. Avdl has set a precedent that allows them to do this so long as the new drug is significantly more beneficial. That point could be argued and proven in so many ways. Even if not entirely true

0 · Reply

Its_Only_Money_369 Sep. 5 at 10:44 PM

$AVDL

0 · Reply

Everest17 Sep. 5 at 3:14 PM

$AVDL Susan sounds pretty sharp. Drop out rates declining Richard must have been a plant from Jazz

2 · Reply

JarvisFlow Sep. 5 at 12:00 PM

HC Wainwright & Co. has updated their rating for Avadel Pharmaceuticals ( $AVDL ) to Buy with a price target of 36.

0 · Reply

Quantumup Sep. 5 at 11:20 AM

H.C. Wainwright⬆️ $AVDL's PT to $36 from $24, reiterated Buy after Avadel announced that it has entered into an exclusive global license agreement with privately-held XWPharma. $CNTA $ALKS $AXSM $JAZZ H.C. Wainwright added, Valiloxybate has been purposefully designed to deliver the therapeutic benefits of oxybate therapy through a once-at-bedtime, salt-free and artificial sweetener-free formulation. In the wake of this transaction, we reiterate our Buy rating, while raising our 12-month price target to $36 from the prior $24 per share. This reflects the addition of valiloxybate to our valuation assessment. We believe that this candidate could be developed via an even more streamlined clinical pathway than LUMRYZ in both narcolepsy and IH, with potential launch in narcolepsy in 2H28 and in IH in 2029.

1 · Reply

AnthonySaba79 Sep. 5 at 1:30 AM

$AVDL how can AVDL be awarded $1 billion in this upcoming settlement with Jazz? Seems a little high to me..

3 · Reply

Otus Sep. 4 at 3:37 PM

$AVDL seems to me this deal puts to bed any takeover chatter. I’ve been saying I didn’t think we were going to be taken over anytime soon. I’m doubling down on that opinion.

2 · Reply

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025

Sep 3, 2025, 4:30 PM EDT - 6 days ago

Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd

Aug 29, 2025, 8:00 AM EDT - 11 days ago

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Aug 8, 2025, 1:45 AM EDT - 4 weeks ago

Avadel Pharmaceuticals plc (AVDL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 4 weeks ago

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2025, 7:00 AM EDT - 4 weeks ago

Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

Jul 31, 2025, 8:00 AM EDT - 5 weeks ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7

Jul 14, 2025, 7:00 AM EDT - 2 months ago

ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders

Jun 30, 2025, 9:41 AM EDT - 2 months ago

ASL pushes for board shakeup at Avadel over handling of sleep drug rollout

Jun 30, 2025, 7:00 AM EDT - 2 months ago

Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation

Jun 29, 2025, 10:30 PM EDT - 2 months ago

ASL Strategic Value Fund targets Avadel board over Lumryz drug mismanagement, WSJ reports

Jun 29, 2025, 9:00 PM EDT - 2 months ago

An investor in the narcolepsy drugmaker Avadel Pharmaceuticals plans to call for shareholders to vote out the company's entire board of directors, ratcheting up pressure

Jun 5, 2025, 7:30 AM EDT - 3 months ago

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

May 29, 2025, 4:05 PM EDT - 3 months ago

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025

May 29, 2025, 8:00 AM EDT - 3 months ago

Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 15, 2025, 11:43 AM EDT - 4 months ago

Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'

May 13, 2025, 4:15 PM EDT - 4 months ago

Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer

May 13, 2025, 8:00 AM EDT - 4 months ago

Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 7, 2025, 12:45 PM EDT - 4 months ago

Avadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 4 months ago

Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

May 6, 2025, 12:30 PM EDT - 4 months ago

Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction

Apr 30, 2025, 8:00 AM EDT - 4 months ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7

Apr 17, 2025, 8:00 AM EDT - 5 months ago

Avadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical Neuroscience

Apr 8, 2025, 1:30 PM EDT - 5 months ago

Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 5 months ago

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians

Mar 3, 2025, 11:53 PM EST - 6 months ago

Avadel Pharmaceuticals plc (AVDL) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 7:00 AM EST - 6 months ago

Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 4:05 PM EST - 7 months ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3

Feb 24, 2025, 8:00 AM EST - 7 months ago

Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

Feb 11, 2025, 6:08 PM EST - 7 months ago

Avadel Pharmaceuticals: Moving To A Speculative Buy

Feb 10, 2025, 9:00 AM EST - 7 months ago

ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors

Jan 13, 2025, 12:56 PM EST - 8 months ago

3 Oversold Biotech Names

FOLD JAZZ VKTX XBI

Jan 12, 2025, 3:26 AM EST - 8 months ago

Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook

Jan 8, 2025, 4:15 PM EST - 8 months ago

Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch

Jan 3, 2025, 8:00 AM EST - 8 months ago

Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8

Nov 13, 2024, 8:00 AM EST - 10 months ago

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Nov 12, 2024, 3:19 PM EST - 10 months ago

Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 7:00 AM EDT - 11 months ago

Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation

Oct 17, 2024, 10:03 AM EDT - 11 months ago

US FDA expands approval for Avadel's sleep disorder drug

Oct 17, 2024, 9:41 AM EDT - 11 months ago

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)

Aug 9, 2024, 12:27 PM EDT - 1 year ago

Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Avadel Pharmaceuticals to Join Russell 3000® Index

May 22, 2024, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024

May 21, 2024, 7:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors

May 8, 2024, 7:00 AM EDT - 1 year ago

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 1, 2024, 8:00 AM EDT - 1 year ago

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8

Apr 2, 2024, 3:40 AM EDT - 1 year ago

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

tagebha Sep. 9 at 4:59 PM

$AVDL Here is a link to patents XWPharma has. https://patents.justia.com/assignee/xwpharma-ltd

0 · Reply

G101SPM Sep. 9 at 2:57 PM

G101SPM 8/7/2025, 7:33:09 AM $AVDL $11.64 bid. DAC (dollar average cost includes 6-transactions with partial SELLS at a profit to reduce cost to $8.98. EXIT $35.00 - LH.

0 · Reply

Its_Only_Money_369 Sep. 5 at 11:23 PM

1 · Reply

Its_Only_Money_369 Sep. 5 at 10:48 PM

0 · Reply

Its_Only_Money_369 Sep. 5 at 10:44 PM

$AVDL

0 · Reply

Everest17 Sep. 5 at 3:14 PM

$AVDL Susan sounds pretty sharp. Drop out rates declining Richard must have been a plant from Jazz

2 · Reply

JarvisFlow Sep. 5 at 12:00 PM

HC Wainwright & Co. has updated their rating for Avadel Pharmaceuticals ( $AVDL ) to Buy with a price target of 36.

0 · Reply

Quantumup Sep. 5 at 11:20 AM

1 · Reply

AnthonySaba79 Sep. 5 at 1:30 AM

$AVDL how can AVDL be awarded $1 billion in this upcoming settlement with Jazz? Seems a little high to me..

3 · Reply

Otus Sep. 4 at 3:37 PM

$AVDL seems to me this deal puts to bed any takeover chatter. I’ve been saying I didn’t think we were going to be taken over anytime soon. I’m doubling down on that opinion.

2 · Reply

Otus Sep. 4 at 1:46 PM

$AVDL I’m assuming thi new deal will be a hot topic on the upcoming conferences avdl is attending. Also, random thought, seems to punch a big hole in Wells Fargo bear thesis. Apparently the wells analyst hadn’t actually spoken to anyone at avdl.

0 · Reply

Otus Sep. 4 at 1:35 PM

$AVDL it appears the market isn’t sure how to interpret this deal yet. Myself included. Would be nice if the had a conference call.

1 · Reply

Alex_Abou_Ezzi Sep. 4 at 1:24 PM

$AVDL wow

1 · Reply

Everest17 Sep. 4 at 10:28 AM

$AVDL This is very significant news. Someone astute, can’t remember if on here or YMB several months ago alluded to this mystery slide deck that evaporated highlighting this exact news. I believe it has been well over a year in the making. And I also believe that the announcement timing was pre-meditated. Interpret the rest as you may.

0 · Reply

Thestocktraderhubzee Sep. 4 at 10:25 AM

WATCHLIST SEP 04 2025. $GE GE Aerospace And BETA Technologies Partner To Accelerate Development Of Hybrid Electric Aviation; GE Aerospace To Make Equity Investment Of $300M In BETA Technologies $AVDL Avadel Pharmaceuticals Enters Exclusive Global License Agreement With XWPharma To Develop and commercialize Valiloxybate For Indications Including Sleep Disorders; XWPharma To Receive $20M Upfront And Potential Milestones $NEXT NextDecade shares are trading higher after the company announced it executed a 20-year liquefied natural gas sale and purchase agreement with EQT for offtake from Rio Grande LNG Train 5. $CWT California Water Service Group Earns "World's Most Trustworthy Companies" Designation by Newsweek for Third Consecutive Year $M Jefferies Maintains Buy on Macy's, Raises Price Target to $18.5

0 · Reply

G101SPM Sep. 4 at 9:51 AM

$AVDL $14.03 bid. DAC (6) $8.98 / last $7.61 (2.28.25). EXIT $35.00 Legacy Holding status. BRIEF: Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd – Expands Avadel’s pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia – – Initial pharmacokinetic (PK) and comparative bioavailability study to initiate in fourth quarter 2025 with pivotal PK trial planned for second half 2026 – – XWPharma to receive $20 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales –

0 · Reply

tagebha Sep. 4 at 12:33 AM

$AVDL Here is the phase 1 trial for the medicine Avadel just licensed. https://www.clinicaltrials.gov/study/NCT04688580?term=AREA%5BInterventionSearch%5D(XW10172)%20AND%20AREA%5BStudyType%5D(INTERVENTIONAL)&rank=2

0 · Reply

tagebha Sep. 4 at 12:30 AM

$AVDL Here is an article about the medics Avadel just licensed. https://www.nature.com/articles/d43747-021-00071-5.

1 · Reply

Willdowdell Sep. 3 at 9:53 PM

$AVDL let’s say AVDL is awarded, for example, 500 million in damages.. how does that money get used by the company, is there any way they’d do a special dividend, etc for shareholders? I’m not aware of any other indications other than IH that they are pursuing currently…

2 · Reply

justanotheropinion Sep. 3 at 9:24 PM

$AVDL I'm only a dumb trader who scans a few recent quarterly earnings & analyzes price & volume action (they all look great), so I can't comment on the work done by Wells Fargo. An overweight rating would've helped the case, but I remain optimistic because of how the market reacted. Today's reaction tells me that while the market acknowledged the analysis, it didn't care that much. The price remains above its fast-moving average (10-day EMA), buyers stepped in and absorbed the selling pressure (green volume delta + largest volume since the earnings report). An example of a stock from the same sector, when the market cared much more after an analyst published his underwhelming rating, was $HALO on 13 May 2025—don't ask me why I remember it so vividly. Overall, $AVDL remains one of my biggest holdings

0 · Reply

profitraider Sep. 3 at 5:49 PM

$AVDL Like I said… this stock is over!

0 · Reply

Otus Sep. 3 at 2:16 PM

$AVDL the wells analyst,Benjamin Barnett, doesn’t appear to have a great track record. Look it up yourself. One of his recent 2025 picks was for chrisper. He had a 48 price target I believe. Chrisper has recently pulled back pretty big and is now trading at 54.65. My opinion is to ignore this analyst.

1 · Reply

Market Cap	1.53B
Revenue (ttm)	169.12M
Net Income (ttm)	-48.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	60.88
Profit Margin	-28.87%
Debt to Equity Ratio	0.00

Volume	1,367,900
Avg Vol	1,309,108
Day's Range	N/A - N/A
Shares Out	97.10M
Stochastic %K	68%
Beta	1.58
Analysts	Strong Sell
Price Target	$18.90